A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

NCT03275454 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Purpura, Thrombocytopenic, Idiopathic

Interventions

DRUG: BIVV009 6.5 grams
DRUG: BIVV009 7.5 grams

Sponsor

Bioverativ, a Sanofi company